Table 2 Posted results of combination regimen trials for pembrolizumab, nivolumab, and atezolizumab in advanced non-small cell lung cancer

NCT02578680

Keynote-189

III

First-line

Treatment-naive metastatic non-squamous NSCLC without EGFR/ALK alteration

Platinum-based CT

18.9%

4.9 months

17.3%

11.3 months

49.4%

65.8%

Platinum-based CT plus pembrolizumab

47.6%

8.8 months

34.1%

NR

69.2%

67.2%

NCT02775435

Keynote-407

III

First-line

Untreated metastatic squamous NSCLC without EGFR/ALK alteration

Carboplatin-based CT

38.4%

4.8 months

NA

11.3 months

48.3%

68.2%

Carboplatin-based CT plus pembrolizumab

57.9%

6.4 months

NA

15.9 months

65.2%

69.8%

NCT02477826

Checkmate-227

III

First-line

Untreated recurrent NSCLC of high mutation burden without EGFR/ALK alteration

Platinum-based CT

26.9%

5.5 months

13.2%

NA

NA

36.0%*

Nivolumab plus Ipilimumab

45.3%

7.2 months

42.6%

NA

NA

37.0%*

NCT02366143

IMpower150

III

First-line

Untreated metastatic non-squamous NSCLC (wild type group)

Bevacizumab plus carboplatin plus paclitaxel (BCP)

48.0%

6.8 months

18.0%

14.7 months^#

60.6%^#

50.0%⁺

Atezolizumab plus BCP

63.5%

8.3 months

36.5%

19.2 months^#

67.3%^#

58.5%⁺

NCT02657434

IMpower131

III

First-line

Untreated metastatic squamous cell NSCLC without EGFR/ALK alteration

Carboplatin-based CT

41.0%

5.6 months

12.0%

13.9 months^#

56.9%^#

58.0%*

Carboplatin-based CT plus atezolizumab

49.0%

6.3 months

24.7%

14.0 months^#

55.6%^#

69.0%*

NCT02657434

IMpower132

III

First-line

Untreated metastatic non-squamous NSCLC without EGFR/ALK alteration

Platinum-based CT

32.0%

5.2 months

17.0%

13.6 months^#

55.4%^#

59.0%

Platinum-based CT plus atezolizumab

47.0%

7.6 months

33.7%

18.1 months^#

59.6%^#

69.0%